ERAS NASDAQ
Credit Risk of going bust: higher than 55% of companies Debt: 0.8% of company value Bonds: none of note held by US funds details ▾
If the stock fell to about $0.03 (down 99.8%), Erasca, Inc. would be worth roughly what it owes.
Total debt $44.7M against a stock market value of $5.32B.
Distance to default 4.62 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $22.4M (short-term plus half of long-term), stock volatility 107.5%; Altman Z'' -3.94. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
San Diego, CA 92121
US
Erasca, Inc. is a biopharmaceutical company in the clinical development stage, primarily focused on identifying, advancing, and commercializing therapeutic solutions for malignancies propelled by the RAS/MAPK pathway. The firm's pipeline features several key experimental drugs: ERAS-007, an orally administered ERK1/2 inhibitor designed to address non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor targeting patients with advanced or metastatic solid tumors. Additionally, Erasca is progressing ERAS-801, an EGFR inhibitor capable of penetrating the central nervous system, intended for recurrent glioblastoma multiforme. The company was founded in 2018 and maintains its headquarters in San Diego, California.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Fuchs Charles S. | A-Award | 1,300,000 | $18.12 | 2026-08-10 |
| Fuchs Charles S. | 0 | — | 2026-08-10 | |
| Start Valerie Denise | A-Award | 29,888 | $16.01 | 2026-06-26 |
| LIU JEAN I | A-Award | 29,888 | $16.01 | 2026-06-26 |
| Multani Pratik S | A-Award | 29,888 | $16.01 | 2026-06-26 |